Intensity Therapeutics' INT230-6 Demonstrates Increased Surv

Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Solid Tumors Patients Receiving a Dose...

Related Keywords

Westport , Illinois , United States , Ottawa , Ontario , Canada , Chicago , American , Edna Kaplan , Merck Sharpe Dohme , Lewish Bender , Jacob Stephen Thomas , Michael Miller , Bristol Myers Squibb , Jacobs Thomas , Development Agreement , Ontario Institute Of Cancer Research , Ottawa Hospital Research Institute , Company On Twitter , American Society Of Clinical Oncology , National Cancer Institute , Prnewswire Intensity Therapeutics Inc , Intensity Therapeutics Inc , Vaccine Branch , Rx Communications Group , Merck Co Inc , Merck Sharp Dohme , Norris Comprehensive Cancer Center , Data Show , Well Tolerated , Elicits Both Direct Tumor Killing , Immune Activating Effects , Median Overall Survival , Population Consisting , Primarily Pancreatic , Bile Duct , Triple Negative Breast Cancer , Been Reached , Median Follow , Clinical Oncology , Annual Meeting , Both Poster , Podium Discussion , First Author , Poster Discussion , Developmental Therapeutics , Discussion Session Date , Live Stream , Intensity Therapeutics , Assistant Professor , Clinical Medicine , Keck School , Southern California , Comprehensive Cancer Center , Keck Medicine , Chief Executive Officer , Response Evaluation Criteria , Solid Tumors , Royal Marsden Hospital Index , Merck Sharpe , Ontario Institute , Cancer Research , Cooperative Research , Intensity Therapeutic , Merck Sharp , Relations Contact , Nc , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Biotechnology , Clinical Trials Amp Medical Discoveries ,